Fibrocell Science, Inc. (OTCBB:FCSC.OB) announced that pivotal clinical trial data demonstrating the effectiveness of LAVIV™ (azficel-T) for the improvement of the appearance of moderate-to-severe nasolabial fold wrinkles (“smile lines&rdquo is published online by Dermatologic Surgery, the official, peer-reviewed publication of the American Society for Dermatologic Surgery. It will also be published in an upcoming print issue. LAVIV is a breakthrough aesthetic treatment made from millions of a person’s own living, cultured, collagen-producing fibroblast cells and then injected into smile line wrinkles. This data supported the FDA approval of LAVIV and the publication is another significant development in the company's stated goal of being the leader in fibroblast evidence-based science.
The publication in Dermatologic Surgery includes the combined results of two identically-designed, Phase III, multi-center, randomized, double-blind, placebo-controlled, studies of 421 patients that showed statistically significant efficacy results for LAVIV. The criteria for a positive response included a 2-point improvement on the Subject Wrinkle Assessment Scale and a 2-point improvement on the Evaluator Wrinkle Assessment Scale for both nasolabial fold wrinkles. LAVIV showed a good safety profile in the studies; the most common adverse events were mild to moderate injection site reactions. See Below for Important Safety Information About LAVIV (azficel-T).
“This large, comprehensive study included strict criteria for demonstrating improvement in the appearance of moderate to severe smile line wrinkles,” said Dr. Stacy R. Smith, Associate Clinical Professor in the Division of Dermatology at the University of California, San Diego and lead author of the publication. “LAVIV is the first personalized cell therapy for aesthetic improvement to show a statistically significant benefit in large, controlled trials,” he added.
The patented technology behind LAVIV is an advanced process that extracts a person’s fibroblast cells from a small skin sample and multiplies them in the Fibrocell Science lab. In normal skin, fibroblasts are responsible for producing collagen. LAVIV is the resulting formulation of a person’s own living, cultured fibroblast cells, which is then injected into smile line wrinkles. Each person’s formulation of LAVIV is unique because it is made from their own fibroblast cells.
“We are pleased that the results of our pivotal clinical trials are now published in a prestigious, peer-reviewed journal such as Dermatologic Surgery,” said David Pernock, Fibrocell Science Chairman and CEO. “Fibrocell Science takes pride in how we design and implement our clinical investigations, proving to the scientific community that our findings are sound.”
About the Publication in Dermatologic Surgery
This analysis combined results from two studies and required a 2-point improvement in both patient and investigator wrinkle assessments. Based on this standard, 30% of subjects who received at least one LAVIV injection had a 2-point improvement in the appearance of smile lines six months after completing treatment, as rated by investigators, versus 8% for placebo. In self-assessments, 59% of patients reported a two-point improvement six months after completing treatment, versus 26% for placebo. See the full prescribing information for LAVIV for results from the each of the two individual studies including the adverse reactions reported in = 1% of subjects. The safety and efficacy of LAVIV for areas other than the nasolabial folds have not been established.
“As the first personalized cellular therapy in aesthetic medicine, LAVIV offers an innovation option to patients who want to improve the appearance of their smile lines without using synthetic substances as active ingredients,” said Dr. Robert A. Weiss, Clinical Associate Professor, Johns Hopkins School of Medicine and Director, Maryland Laser Skin & Vein Institute, and also study author. “The safety profile of LAVIV is very good since it’s made from a patient’s own living, cultured fibroblast cells.”
“The positive effects of LAVIV were maintained six months after the third injection,” added Girish (Gilly) Munavalli, M.D., Medical Director, Dermatology, Laser, and Vein Specialists of the Carolinas, PLLC, Assistant Professor of Dermatology at Wake Forest University School of Medicine, and another study author. “It was exciting to see that LAVIV showed no signs of degradation during this time and that the effect persisted. The efficacy of LAVIV beyond six months hasn’t yet been evaluated in adequate and well controlled clinical trials.”
About LAVIV™ (azficel-T)
LAVIV was approved by the FDA on June 21, 2011 for the improvement of the appearance of moderate-to-severe nasolabial fold wrinkles in adults and is the first and only personalized cell therapy approved by the FDA for aesthetic use. LAVIV is now available in major metropolitan areas throughout the U.S., exclusively through board-certified dermatologists and plastic surgeons who have been trained by Fibrocell Science on the treatment process. A list of trained and certified physicians is available at www.mylaviv.com and will be continually updated as new physicians are trained and begin offering LAVIV in their practice.
Fibrocell Science is conducting research to identify other potential uses of LAVIV and their proprietary fibroblast technology. There is no timeline regarding when Fibrocell Science will seek FDA regulatory approval for additional uses.
Important Safety Information About LAVIV™ (azficel-T)
LAVIV is made especially for you from your own skin cells. Using someone else’s cells can cause a serious reaction. Prior to injection, confirm with your physician that your information on the LAVIV vial is correct. The most common side effects of LAVIV are at the injection-site, including redness, bruising, swelling, pain, bleeding, lumps, irritation, and itchiness. In clinical trials with LAVIV, most injection-site adverse reactions resolved within one week and most required no treatment.
Your health care provider will help you to decide whether you are a candidate for LAVIV and may help you avoid some of the adverse reactions from LAVIV. Before getting LAVIV, tell your healthcare provider if you have any medical problems including allergic reactions to any drugs or food, bleeding disorders or take blood-thinning medicines like aspirin, ibuprofen, or Coumadin® (warfarin sodium), keloids or excessive scarring, skin cancer or any malignancy, genetic disorders affecting your skin, immune problems or take medicines that affect your immune system, or any other illness or medical problem. The full Prescribing Information for LAVIV includes additional warnings about adverse reactions that occurred in less than 1% of patients following LAVIV treatment in clinical trials. Talk to your healthcare provider about these warnings.
Please tell your healthcare provider if you are allergic to the antibiotics amphotericin or gentamicin, bovine materials (products made from cattle), or dimethyl sulfoxide (DMSO). Do not use LAVIV if you have a skin infection on your face because LAVIV treatment can make the infection worse.
For more information about LAVIV, please see the Full Prescribing Information at www.mylaviv.com.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (OTCBB:FCSC.OB) is an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.
Posted On: 04/18/2012 2:23:55 PM
Post# of 1842
(0)
(0)
Top 10 Most Recent Blog Posts
Tilray Brands, Inc. (TLRY): A Global Cannabis Leader
Category: Stocks Total Views: 113
By : Kelly Martin Updated: 07-29-2024
Overview of Tilray Brands, Inc.
Tilray Brands, Inc. (NASDAQ: TLRY) is a pioneering company in the field of medical and recreational cannabis production and research. Headquartered in Canada, Tilray has positioned itself as a global leader with a commitment to providing safe, consistent, and reliable therapy to patients and consumers worldwide. The company operates in multiple regions, including Canada, the United States, Europe, Australia, and Latin America, serving a diverse clientele rangin... Continue Reading
Understanding the Demand Generation Process for Business Growth
Category: Business Total Views: 130
By : Ryan Hughes Updated: 07-29-2024
Introduction to Demand Generation
In the fast-paced world of digital marketing and advertising, understanding the demand generation process is crucial for business growth. Demand generation is a comprehensive strategy aimed at creating awareness and interest in a company's products or services, ultimately driving customer engagement and revenue. For advertisers, especially in the realm of connected TV advertising, mastering demand generation can significantly enhance performance marketing... Continue Reading
Philips Unveils New AI Cardiovascular Ultrasound Platform
Category: Stocks Total Views: 127
By : Henry Turner Updated: 07-29-2024
Philips Reports Strong Order Intake Growth in Q2 2024
With a 9% rise over past periods, Philips's order intake in Q2 2024 rose significantly. Mostly, the North American market drove this expansion. With group sales of EUR 4.5 billion, the company said that comparable sales had risen by 2%. Operations brought in EUR 816 million, of which EUR 538 million came from insurance earnings. The changed EBITA margin climbed to 11.1% of sales. Apart from a free cash outflow of EUR 64 million, Philip... Continue Reading
High-Purity Canola Protein: Burcon’s New Achievement
Category: Stocks Total Views: 160
By : Dominic Sanders Updated: 07-29-2024
Burcon NutraScience Achieves Milestone in Canola Protein Production
Leader in plant-based protein technologies, Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) has effectively finished its first end-to-end validation trial for manufacturing high-purity canola protein isolate. For Burcon's goal of releasing creative, plant-based protein solutions onto the market, this success represents a major forward step.
Commercialization of Canola Protein Technology
Burcon's commerc... Continue Reading
Cosa's Orbit Project Gains Untapped Exploration Areas
Category: Stocks Total Views: 162
By : Caleb Price Updated: 07-29-2024
Acquisition of Mineral Claims in Athabasca Basin
Skyharbour Resources LTD. has signed an asset purchase agreement with Cosa Resources Corp. Signed July 26, 2024, the agreement calls for acquiring two mineral claims in the Athabasca Basin, Saskatchewan. With 12,718 hectares, these claims will double the footprint of the Orbit uranium project. With this purchase, Cosa will be able to increase its eight kilometer control of untested strike length. The claims follow trend with uranium mineralizat... Continue Reading
Hyperfast Title Joins reAlpha's AI Homebuying Platform
Category: Stocks Total Views: 193
By : Riley Hayes Updated: 07-29-2024
reAlpha Acquires 85% Stake in Hyperfast Title, LLC
85% of Hyperfast Title, LLC. has been acquired by reAlpha Tech Corp. Hyperfast calls Florida, Virginia, and Tennessee home. This purchase expands the portfolio of reAlpha with title and settlement services. Re Alpha is renowned for creating real estate artificial intelligence technologies. The purchase from Madison Settlement Services fits the expansion plan of reAlpha. This action enhances the homebuying market offerings from reAlpha. The in... Continue Reading
Long-term Projections for AI Technologies Development
Category: Business Total Views: 159
By : Hannah Lewis Updated: 07-29-2024
The Rise of Generative AI: Transforming Industries and Investment Strategies
By allowing the creation of fresh content—text and images as well as music and design—generative artificial intelligence is changing sectors. Companies use this technology to improve operations and boost inventiveness. Generative artificial intelligence creates tailored marketing materials in advertising, so boosting interaction. In the medical field, it helps with new medical imaging creation and drug di... Continue Reading
New Alzheimer's Treatment: Anavex's Blarcamesine Success
Category: Stocks Total Views: 238
By : Addison Perry Updated: 07-29-2024
Anavex Life Sciences Reports Promising Results for Alzheimer's Treatment
From its Phase IIb/III study on blarcamesine (ANAVEX®2-73), a medication for early Alzheimer's disease (AD), Anavex Life Sciences Corp. (Nasdaq: AVXL) has reported encouraging findings. Leading neurology specialist Dr. Marwan Noel Sabbagh delivered the data at the 2024 Alzheimer's Association International Conference (AAIC). Taken once daily, blarcamesine has shown great promise in halting the advance of ... Continue Reading
Windtree's Latest Advances: Istaroxime Clinical Trials
Category: Stocks Total Views: 287
By : Lucas Young Updated: 07-28-2024
Windtree Therapeutics Updates Istaroxime Clinical Development and Trial Data
Providing a thorough update on the clinical and business development of istaroxime, Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company committed to developing creative therapies for critical diseases, has This first-in-class treatment seeks to raise blood pressure, preserve or increase renal function, and strengthen systolic contraction and diastolic relaxation of the heart. In three Phase 2 trials... Continue Reading
SEC Charges Citron Capital in Multi-Year Fraud Scheme
Category: Investing Total Views: 267
By : Evelyn Baker Updated: 07-28-2024
SEC Charges Andrew Left and Citron Capital in $20 Million Fraud Scheme
Andrew Left and his company, Citron Capital LLC, have been charged with a $20 million fraud by the Securities and Exchange Commission (SEC). They are activists short sellers. The SEC complaint claims Left recommended stock positions using his Citron Research website and social media platform. He said these positions complemented Citron Capital's and his own investments. Left's recommendations, according to the SEC,... Continue Reading